期刊文献+

von Hippel-Lindau病的分子机制研究 被引量:2

Molecular Mechanism of von Hippel-Lindau Disease
下载PDF
导出
摘要 VHL病(vonHippel-Lindaudisease)是一种遗传性肿瘤综合征,由VHL抑癌基因突变引起。研究表明,VHL蛋白在体内具有多种功能,VHL基因突变形式和部位的差异所造成的VHL蛋白功能增加、减少或缺失可能是导致肿瘤不同表型的重要原因。 VHL disease(von Hippel-Lindau disease) is a kind of hereditary cancer syndrome associated with the mutation of VHL anti-oncogene. It had been implied that VHL could play several roles in vivo, and the addition, reduction or deletion of pVHL protein function may be responsible for different phenotypes of tumor as a result of the difference in mutant forms and sites.
作者 袁翔 胡宝成
出处 《生物技术通讯》 CAS 2005年第2期194-196,共3页 Letters in Biotechnology
关键词 VHL病 缺氧诱导因子-1 泛素连接酶 遗传性肿瘤综合征 发病机制 基因突变 von Hippel-Lindau disease hypoxia-inducible factor-1 E3
  • 相关文献

参考文献47

  • 1Seizinger BR, Rouleau GA, Ozelius LJ, et al. Identification of the von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma[J]. Nature, 1988,332:268.
  • 2Latif F, Tory K, Gnarra J, et al. Identification of the yon Hippel-Lindau disease tumor suppressor gene[J]. Science, 1993,260:1317.
  • 3Iliopoulos O, Kibel A, Gray S, et al. Tumor suppression by the human yon Hippel-Lindau gene product[J]. Nat Med, 1995,1:822.
  • 4Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the yon Hippel-Lindau gene arising from internal translation initiation [J]. Proc Natl Acad Sci USA, 1998,95:11661.
  • 5Blankenship C, Naglich JG, Whaley JM, et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity[J]. Oncogene, 1999,18:1529.
  • 6Schoenfeld A, Davidowitz EJ, Burk RD, et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site,functions as a tumor suppressor[J]. Proc Natl Acad Sci USA, 1998,95:8817.
  • 7Renbaum P, Duh FM, Latif F, et al. Isolation and characterization of thefull-length 3' untranslated region of the human yon Hippel-Lindau tumor suppressor gene[J]. Hum Genet, 1996,98:666.
  • 8Zbar IL Kishida T, Chen F, et al. Germline mutations in the yon Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan[J]. Hum Mutat, 1996,8:348.
  • 9Tory K, Brauch H, Linehan M, et al. Specific genetic change in tumors associated with yon Hippel-Lindau disease[J]. J Natl Cancer Inst, 1989,81:1097.
  • 10Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in yon Hippel-Lindau disease: correlations with germline VHL gene mutations[J]. J Med Genet, 1996,33:328.

同被引文献47

  • 1田俊强,王志平.自体肾移植的研究进展[J].国际泌尿系统杂志,2006,26(4):449-452. 被引量:5
  • 2李金贵,胡自力.肾动脉介入栓塞在肾癌治疗中的应用[J].重庆医学,2007,36(11):1100-1103. 被引量:3
  • 3叶元平,梁朝朝,张贤生,郝宗耀,周骏,刘明,邢江,邢江湜,蒋云仙,王克孝.保留肾单位手术治疗肾癌(附46例报告)[J].临床泌尿外科杂志,2007,22(8):572-574. 被引量:7
  • 4Akcaglar S, Yavascaoglu I, Vuruskan H, et al. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis. Int Urol Nephrol, 2008, 40(3) : 615-620.
  • 5Barontini M, Dahia PL. VHL disease. Best Pract Res Clin Endocrinol Metab, 2010, 24(3): 401-413.
  • 6Hayden MG, Gephart R, Kalanithi P, et al. Von Hippel-Lindau disease in pregnancy: a brief review. J Clin Neurosci, 2009, 16(5): 611-613.
  • 7Kim JJ, Rini BI, Hansel DE.Von Hippel Lindau syndrome. Adv Exp Med Biol, 2010, 685(21): 228-249.
  • 8Gijtenbeek JM, Jacobs B, Sprenger SH, et al. Analysis of yon hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg, 2002, 97(4) : 977-982.
  • 9Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of yon Hippel-Lindau disease. Human Mutation, 2010, 31(5) : 521-537.
  • 10Ivanov SV, Ivanova AV, Salnikow K, et al. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up- regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun, 2008, 370(4) : 536-540.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部